The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its position within the broader sector now raises questions about long-term returns . Generic versions are diminishing patent protection , causing worries that supporting companies significantly dependent to Viagra's once-dominant position could be a dang